论文部分内容阅读
目的观察多西他赛与吡柔比星分别联合CTX(环磷酰胺)、5-Fu(5-氟尿嘧啶)化疗对转移性乳腺癌患者的干预效果。方法选取驻马店市第一人民医院2012年1月—2014年1月期间收治的84例转移性乳腺癌患者为研究对象,随机分为A、B两组,每组42例,给予A组多西他赛联合CTX、5-Fu化疗,给予B组吡柔比星联合CTX、5-Fu化疗;21d为一个周期。比较两组临床疗效与不良反应发生情况,并随访2年了解其复发与转移情况。结果 A组RR为88.10%显著高于B组72.22%(P<0.05);A组不良反应率为19.05%显著低于B组40.48%(P<0.05);A组继发远处转移率、局部区域复发率依次为12.50%、10.00%显著低于B组33.33%、28.21%(P<0.05)。结论与吡柔比星相比,多西他赛联合CTX、5-Fu化疗对转移性乳腺癌患者干预的临床疗效更显著,不良反应率、复发率及远处转移率更低,安全可靠,推荐临床使用。
Objective To observe the effect of docetaxel and pirarubicin combined with CTX (cyclophosphamide) and 5-Fu (5-fluorouracil) chemotherapy in patients with metastatic breast cancer. Methods 84 cases of metastatic breast cancer admitted to the First People’s Hospital of Zhumadian City from January 2012 to January 2014 were randomly divided into A and B groups, 42 cases in each group, His race combined with CTX, 5-Fu chemotherapy, given group B pirarubicin combined with CTX, 5-Fu chemotherapy; 21d for a cycle. The clinical efficacy and adverse reactions of the two groups were compared and followed up for 2 years to understand the recurrence and metastasis. Results The RR of group A was 88.10%, which was significantly higher than that of group B 72.22% (P <0.05). The rate of adverse reactions in group A was 19.05%, significantly lower than that in group B 40.48% (P <0.05) The local recurrence rates were 12.50% and 10.00%, respectively, significantly lower than those in group B (33.33% and 28.21%, P <0.05). Conclusions Compared with pirarubicin, docetaxel combined with CTX and 5-Fu chemotherapy is more effective in treating patients with metastatic breast cancer, and its adverse reaction rate, recurrence rate and distant metastasis rate are lower and safe. Clinical use.